Aims: To examine the outcomes of leiomyomas classified by FIGO in relation to the demographic, clinical, and laboratory characteristics of patients who underwent laparotomic myomectomy.
Methods: A total of 199 patients were found between September 2019 and September 2023 according to the criteria for study. Data were analyzed and compared in terms of FIGO leiomyoma classification, leiomyoma size, admission symptoms, body-mass index (BMI) and parity. All demographical and operational features were compared in each group for issues including leiomyomas >8 cm, <8 cm; single or multiple leiomyomas; BMI >30, <30; multiparous and nulliparous patients. Moreover, patients’ admission symptoms as abnormal uterine bleeding, pelvic pain and compression were also recorded and compared.
Results: The mean leiomyoma size, compression symptoms and pelvic pain of those with abnormal uterine bleeding was 8.5±3.2 cm, 9.6±3.1 cm, and 10.9±3.6 cm; respectively. The mean leiomyoma size of individuals with pelvic pain was significantly larger than that of those with abnormal uterine bleeding (p<0.05). Nulliparous patients exhibited a higher incidence of multiple myomas than multiparous patients. Nulliparous patients experienced a lower incidence of abnormal uterine hemorrhage than multiparous patients; however, the incidence of pelvic pain and pressure symptoms was more common (p=0.013). The mean leiomyoma size of those with BMI <30 and BMI ≥30 was 9.8±3.6 cm, and 9.2±3.1 cm; respectively. No statistically significant difference was observed between these groups in terms of mean leiomyoma size, operation time, hospital stay and postoperative complications (p>0.05).
Conclusion: When evaluating laparotomic myomectomy patients, the patient’s parity status, location and size of the leiomyoma should be taken into consideration before surgery.
Amaç: Çalışmamızın amacı, laparotomik miyomektomi geçiren hastaların demografik, klinik ve laboratuvar özelliklerini ve FIGO tarafından sınıflandırılan leiomyomaların sonuçlarını incelemekti.
Gereç ve yöntemler: Eylül 2019 ile Eylül 2023 arasında çalışma kriterlerine göre toplam 199 hasta bulundu. Veriler FIGO leiomyoma sınıflandırması, leiomyoma boyutu, yatış semptomları, vücut kitle indeksi (VKİ), parite açısından analiz edildi ve karşılaştırıldı. Her grupta tüm demografik ve operasyonel özellikler, leiomyomalar > 8 cm, < 8 cm; tek veya çoklu leiomyomalar; VKİ > 30, < 30; multipar ve nullipar hastalar dahil olmak üzere sonuçlar açısından karşılaştırıldı. Ayrıca, anormal uterin kanama, pelvik ağrı ve bası gibi yatış semptomları da kaydedildi ve karşılaştırıldı.
Sonuçlar: Pelvik ağrısı olan hastalarda ortalama leiomyoma boyutunun anormal uterin kanaması olanlara göre daha büyük olduğu bulundu. Nullipar hastalarda, multipar hastalara göre daha yüksek oranda multipl miyom görüldüğü bulundu. Nullipar hastalarda, multipar hastalara göre anormal uterin kanama insidansı daha düşük bulundu; ancak, pelvik ağrı ve bası semptomlarının insidansı artmıştı.. BMI <30 olanların ortalama leiomyoma boyutu 9,8±3,6 cm, BMI ≥30 olanların ortalama leiomyoma boyutu ise 9,2±3,1 cm bulundu. Gruplar arasında ortalama leiomyoma boyutu, operasyon süresi, hastanede kalış süresi ve postoperatif komplikasyonlar açısından istatistiksel olarak anlamlı bir fark gözlenmedi
Sonuçlar: Laparotomik miyomektomi hastaları değerlendirilirken, hastanın parite durumu, leiomyomanın yeri ve boyutu ameliyattan önce dikkate alınmalıdır.
Primary Language | English |
---|---|
Subjects | Obstetrics and Gynaecology |
Journal Section | Original Article |
Authors | |
Publication Date | March 21, 2025 |
Submission Date | December 5, 2024 |
Acceptance Date | March 3, 2025 |
Published in Issue | Year 2025 Volume: 8 Issue: 2 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.